Ito Takahiko, Honma Yoshitaka, Hirano Hidekazu, Shoji Hirokazu, Okita Natsuko, Iwasa Satoru, Takashima Atsuo, Kato Ken, Boku Narikazu
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Anticancer Res. 2019 Jul;39(7):3931-3936. doi: 10.21873/anticanres.13545.
BACKGROUND/AIM: Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC). In this retrospective study, we evaluated the efficacy and safety of S-1 monotherapy as a salvage line treatment for RM-ESCC, focusing on the reasons for discontinuation of prior FP.
The subjects of this study had RM-ESCC and received S-1 after failure of FP.
Eleven patients were enrolled. Nine patients were refractory and two were intolerant to prior FP. The median progression-free survival and overall survival time were 3.0 and 11.7 months, respectively. Overall response rate was 22.2% and disease control rate of the 11 patients was 36.4%. Median relative dose intensity of 5-FU was 100% (range=85-100%).
S-1 efficacy in RM-ESCC when given after FP was modest. Favorable OS may be attributed to good local control rather than to the efficacy of S-1 monotherapy.
背景/目的：顺铂联合5-氟尿嘧啶（FP）是复发或转移性食管鳞状细胞癌（RM-ESCC）姑息化疗的一线方案。在这项回顾性研究中，我们评估了S-1单药作为RM-ESCC挽救治疗的疗效和安全性，重点关注先前FP治疗中断的原因。
本研究的受试者为RM-ESCC患者，在FP治疗失败后接受S-1治疗。
共纳入11例患者。9例患者对先前的FP治疗耐药，2例不耐受。无进展生存期和总生存期的中位数分别为3.0个月和11.7个月。总缓解率为22.2%，11例患者的疾病控制率为36.4%。5-氟尿嘧啶的相对剂量强度中位数为100%（范围=85-100%）。
FP治疗后给予S-1治疗RM-ESCC的疗效一般。总生存期良好可能归因于良好的局部控制，而非S-1单药治疗的疗效。
Zotero 插件